A-Eye Help Unpack Studies of Protection from Spike Protein SARS-CoV-2, from Natto

stock here: this was helpful

https://www.thefocalpoints.com/p/dissolution-of-spike-protein-by-nattokinase

I’ll analyze the charts in the image and explain the data clearly. Let me extract the relevant details.
Explanation of the Charts in the Image

The study appears to analyze the degradative effect of Nattokinase on the SARS-CoV-2 spike protein using biochemical assays and cell viability tests.
Panel (B) – Area Ratio [S Protein/Nuclei]

This graph measures the relative amount of spike protein compared to the number of cell nuclei.
The Y-axis represents the area ratio of S protein to nuclei (no specific units given, but it shows relative quantification).
The X-axis compares control (untreated cells) vs. cells treated with Nattokinase at two concentrations:
    25 µg/ml
    2.5 µg/ml
Findings:
    The control group (untreated) has a high level of spike protein.
    Nattokinase at 25 µg/ml shows a drastic reduction in spike protein.
    Nattokinase at 2.5 µg/ml also reduces spike protein, but less effectively than the higher dose.
    The "*****" (statistical significance) suggests that the reduction in spike protein is statistically significant.

Panel (C) – Cell Viability

This measures how healthy the cells remain after treatment with Nattokinase.
The Y-axis represents percentage of viable cells (relative to control, set at 100%).
The X-axis compares:
    Control (untreated cells)
    Nattokinase (25 µg/ml)
    Nattokinase (2.5 µg/ml)
Findings:
    Both Nattokinase concentrations do not significantly affect cell viability.
    This suggests that Nattokinase degrades the spike protein without killing cells, making it a potential safe treatment.

Panel (C) – Western Blots for Spike Protein and ACE2

Western blot images show protein degradation.
Leftmost blot (S Protein):
    The S protein band is strong in the control and PBS groups (showing presence of spike protein).
    Nattokinase-treated lanes show much weaker bands, confirming spike protein degradation.
    The "heat-treated Nattokinase" (negative control) does not degrade spike protein, indicating that the enzyme activity is needed.
Middle blot (RBD-sfGFP fusion protein):
    Nattokinase degrades RBD (Receptor Binding Domain), reducing the viral binding ability.
Rightmost blot (ACE2 protein):
    ACE2, the human receptor for SARS-CoV-2, is not affected by Nattokinase.
    This shows that Nattokinase specifically targets the spike protein and does not harm ACE2, which is crucial for normal cell function.

Summary of Key Findings

Nattokinase significantly reduces spike protein levels in a dose-dependent manner.
It does not kill human cells, suggesting it is safe at tested doses.
The enzyme specifically degrades the viral spike protein without affecting ACE2, making it a promising candidate for reducing viral attachment.